NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for depression, PTSD, and suicide prevention.
The company is expected to release its Q4 2025 earnings (and potentially full-year 2025 results) around mid-to-late March 2026. Analyst estimates for the upcoming quarterly report vary across sources, but recent consensus points to an expected loss per share of approximately -$0.09 and projected revenue of around $7.53 million. Recent company announcement indicates a conference call on March 24, 2026, at 8:00 AM ET to discuss full-year 2025 financial results and provide a corporate update on drug development and the HOPE Therapeutics clinical network. This aligns with the company's mission to improve patient lives through innovative treatments.
Despite these efforts, NRXP faces significant financial challenges as a pre-commercial biotech with limited revenue to date. The company has a negative trailing P/E ratio (around -1.07), confirming it is not currently profitable. The price-to-sales (P/S) ratio is very high at approximately 135–138.
The enterprise value to sales ratio is even higher, recently reported around 258–264, underscoring the elevated valuation relative to current revenue. The enterprise value to operating cash flow ratio remains negative (consistent with ongoing cash burn), highlighting difficulties in generating positive cash flow from operations.
NRXP's financial health is strained by a deeply negative earnings yield (implied by the negative P/E and large losses) and negative shareholders' equity (leading to a negative book value per share of around -$0.93). The debt-to-equity ratio is effectively near zero, but the company carries minimal traditional debt. The current ratio of 0.29 (as of the most recent quarter) indicates potential liquidity concerns, as current assets may not sufficiently cover short-term liabilities without additional financing or revenue growth.
